FlashMed

Titolo	Hemodialysis membranes for high-volume hemodialytic therapies: the application of nanotechnology
Autore	C. Ronco, B. Breuer, S.K. Bowry
Referenza	Hemodialysis International 2006; 10: S48-S50
Contenuto	In recent years, much attention has been devoted to the various issues around the poor survival rates of patients on routine hemodialysis. A wealth of data now exists showing both poor patient outcomes and a poorer quality of life of dialysis patients worldwide.1 The challenging task to improve this bleak situation is being addressed by diverse factions of the dialysis fraternity, involving nephrologists, nurses, scientists, technicians, statisticians, and of course industry which is the provider of devices, instrumentation, as well as a whole spectrum of patient-care services. It has also become apparent that dialysis patient mortality attributed to cardiovascular events is unacceptably higher than that for the general population. Patients on maintenance dialysis have a several-fold higher risk of death from cardiovascular disease than individuals of the general population. Indeed, the fact that a 25-year-old dialysis patient has approximately the same risk of death as an 85-year-old person from the general population clearly emphasizes the predicament of all involved in the care of the dialysis patient. A number of separate issues that may influence the poor outcomes have been delineated and are being addressed in recent years. The effect of comorbid conditions, residual renal function and time of referral to dialysis, the aging dialysis population, medication and the type, duration and frequency of the hemodialysis therapy being administered are just some of the issues we are confronted with. In this paper we look at some of the aspects pertaining to the choice of the therapy modality which may further be related to the issue of patient outcomes.
Data	17.02.2006

Lista completa